Abstract: The present invention relates to methods for treating and preventing renal impairment by administering to a subject a therapeutically effective amount of an A1 adenosine receptor antagonist alone or in combination with at least one additional therapeutic agent. The invention further encompasses pharmaceutical compositions comprising an A1 adenosine receptor antagonist alone or with, at least, one additional therapeutic agent in a pharmaceutically acceptable carrier. The pharmaceutical compositions of the invention find use in methods for treating and preventing renal impairment.

Abstract: This invention relates to compounds of formula (I), Wherein R1-R4 are defined in the Specification, their uses in the practice of medicine, their medicinal formulations, their use in medical diagnosis, and their preparation.

Abstract: The present invention relates to methods for treating and preventing renal impairment by administering to a subject a therapeutically effective amount of an A1 adenosine receptor antagonist alone or in combination with at least one additional therapeutic agent. The invention further encompasses pharmaceutical compositions comprising an A1 adenosine receptor antagonist alone or with, at least, one additional therapeutic agent in a pharmaceutically acceptable carrier. The pharmaceutical compositions of the invention find use in methods for treating and preventing renal impairment.

Abstract: This invention relates to compounds of formula (I), Wherein R1-R4 are defined in the Specification, their uses in the practice of medicine, their medicinal formulations, their use in medical diagnosis, and their preparation.

Abstract: The present invention relates to the methods of use for measurement of lipopolysaccharide (LPS) and methods of use for diagnosis of sepsis and LPS-related conditions. Specifically the present invention relates to a time resolved fluorescence (TRF) based assay for the measurement of LPS and methods of use for the measurement of LPS to diagnose sepsis, Gram-negative bacterial infections, and LPS-related conditions.

Abstract: Compounds of the general formula (I) are described: wherein A is a 5- or 6-membered aromatic or heteroaromatic ring. Compositions comprising such compounds and methods of use thereof are also described.

Abstract: Subjects at risk for developing cancer may be identified by obtaining samples of diagnostic cells from the subjects and determining a measure of cytotoxicity of the cells, the measure of cytotoxicity correlating negatively with the risk of developing cancer. The development of cancer may be prevented in subjects determined to be at risk for developing cancer by administering priming and activating agents to the subject, by increasing the expression of A1 adenosine receptors in cells of the subject, and increasing the affinity of cells of the subject for A1 adenosine receptor ligands. The preventative and diagnostic methods of the present invention may be carried out with kits and pharmaceutical liposomal formulations.

Abstract: Compounds of the general formula (I) are described: wherein A is a 5- or 6-membered aromatic or heteroaromatic ring. Compositions comprising such compounds and methods of use thereof are also described.

Abstract: Glycolipids are useful for enhancing the affinity of A1 adenosine receptor ligands for the A1 adenosine receptor. Glycolipids are accordingly useful in diagnostic and therapeutic methods that require the delivery or administration of A1 adenosine ligands.

Abstract: A1 adenosine receptor antagonists and P2X purinoceptor antagonists are useful in the treatments of disorders of the immune system, which include HIV infection, AIDS, and adenosine deaminase deficiency-dependent severe immunodeficiency disease (ADA SCID).

Abstract: Methods of treating and/or imaging tumors utilize A1 adenosine-receptor activated cells (such as monocytes and macrophages) are described. Activated cells may be administered systemically or locally, and may be radiolabelled to provide imaging and diagnostic functions. Macrophages resident in tissues may be primed and activated for use in treating and imaging tumors.

Abstract: Subjects at risk for developing cancer may be identified by obtaining samples of diagnostic cells from the subjects and determining a measure of cytotoxicity of the cells, the measure of cytotoxicity correlating negatively with the risk of developing cancer. The development of cancer may be prevented in subjects determined to be at risk for developing cancer by administering priming and activating agents to the subject, by increasing the expression of A1 adenosine receptors in cells of the subject, and increasing the affinity of cells of the subject for A1 adenosine receptor ligands. The preventative and diagnostic methods of the present invention may be carried out with kits and pharmaceutical liposomal formulations.

Abstract: A compound useful as an A1 adenosine receptor antagonist has the formula: wherein R1 is selected from the group consisting of C1-C8 alkyl; R2 is of the formula: R3 is of the formula: —(CH2)qC6H4—R7 R4 is of the formula:

Abstract: Methods of treating and/or imaging tumors utilize A.sub.1 adenosine-receptor activated cells (such as monocytes and macrophages) are described. Activated cells may be administered systemically or locally, and may be radiolabelled to provide imaging and diagnostic functions. Macrophages resident in tissues may be primed and activated for use in treating and imaging tumors.

Abstract: A compound useful as an A.sub.1 adenosine receptor antagonist has the formula: ##STR1## wherein R.sub.1 is selected from the group consisting of C.sub.1 -C.sub.8 alkyl;R.sub.2 is of the formula: ##STR2## wherein n is an integer ranging from 1 to 8; R.sub.5 is H or (CH.sub.2).sub.p, wherein p is an integer ranging from 1 to 8; and R.sub.6 is H or (CH.sub.2).sub.m OH, wherein m is an integer ranging from 1 to 8;R.sub.3 is of the formula:--(CH.sub.2).sub.q C.sub.6 H.sub.4 --R.sub.7wherein q is an integer ranging from 1 to 8; and wherein R.sub.7 is selected from the group consisting of H, NH.sub.2, (CH.sub.2).sub.t OH, wherein t is an integer ranging from 1 to 8; and R.sub.9 COOH, wherein R.sub.9 is an alkyl or alkylidene group having 1 to 8 carbon atoms; andR.sub.4 is of the formula: ##STR3## wherein R.sub.8 is selected from the group consisting of H; NH.sub.2 ; (CH.sub.2).sub.s OH, wherein s is an integer ranging from 1 to 8; and R.sub.10 COOH, wherein R.sub.

Abstract: A compound useful as an A.sub.1 adenosine receptor antagonist has the formula: ##STR1## wherein R.sub.1 is selected from the group consisting of C.sub.1 -C.sub.8 alkyl;R.sub.2 is of the formula: ##STR2## wherein n is an integer ranging from 1 to 8; R.sub.5 is H or (CH.sub.2).sub.p, wherein p is an integer ranging from 1 to 8; and R.sub.6 is H or (CH.sub.2).sub.m OH, wherein m is an integer ranging from 1 to 8;R.sub.3 is of the formula:--(CH.sub.2).sub.q C.sub.6 H.sub.4 --R.sub.7wherein q is an integer ranging from 1 to 8; and wherein R.sub.7 is selected from the group consisting of H, NH.sub.2, (CH.sub.2).sub.t OH, wherein t is an integer ranging from 1 to 8; and R.sub.9 COOH, wherein R.sub.9 is an alkyl or alkylidene group having 1 to 8 carbon atoms; andR.sub.4 is of the formula: ##STR3## wherein R.sub.8 is selected from the group consisting of H; NH.sub.2 ; (CH.sub.2).sub.t OH, wherein s is an integer ranging from 1 to 8; and R.sub.10 COOH, wherein R.sub.